A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years
Completed
Newcastle-upon-Tyne Hospitals NHS Trust
Phase 2
2004-01-01
RATIONALE: Drugs used in chemotherapy, such as vinblastine, cyclophosphamide, procarbazine,
prednisolone, etoposide, mitoxantrone, and bleomycin, work in different ways to stop cancer
cells from dividing so they stop growing or die. Combining more than one chemotherapy drug
may kill more cancer cells.
PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating
older patients with previously untreated Hodgkin's lymphoma.
The purpose of the study is to determine whether corticosteroids are beneficial to children
with bronchiolitis whose breathing gets better after being given a breathing treatment with
albuterol.
Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)
Terminated
Elan Pharmaceuticals
Phase 4
2010-09-01
The objectives of this study are to explore the effects of administering high-dose
corticosteroids to participants who developed progressive multifocal leukoencephalopathy
(PML) while on natalizumab as measured by time-course change in functional status based on
Karnofsky Performance Status Index through 6 months following the completion of plasma
exchange (PLEX; or equivalent), survival at 6 months following the completion of PLEX (or
equivalent), and incidence and severity of adverse events (AEs) and serious adverse events
(SAEs); to characterize the evolution of immune reconstitution inflammatory syndrome (IRIS)
as measured by time course changes in Global Clinical Impression of Improvement (GCI-I),
Symbol Digit Modalities Test (SDMT), brain magnetic resonance imaging (MRI),
magnetoencephalography (MEG), chemokines, cytokines, C-reactive protein (CRP), John
Cunningham virus (JCV) load and cell count in cerebrospinal fluid (CSF); and to characterize
the time course elimination of serum natalizumab concentrations in the study population
following the last PLEX (or equivalent) procedure.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
